Leveraging lessons learned from the COVID-19 pandemic for HIV

Thomas Calder; Tina Tong; Dale J Hu; Jerome H Kim; Karen L Kotloff; Richard A Koup; Mary A Marovich; M Juliana McElrath; Sarah W Read; Merlin L Robb; Philip O Renzullo; M Patricia D'Souza

doi:10.1038/s43856-022-00175-8

Leveraging lessons learned from the COVID-19 pandemic for HIV

Commun Med (Lond). 2022 Aug 29:2:110. doi: 10.1038/s43856-022-00175-8. eCollection 2022.

Authors

Affiliations

¹ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA.
² International Vaccine Institute, Seoul, Republic of Korea.
³ University of Maryland School of Medicine, Baltimore, MD USA.
⁴ Fred Hutchinson Cancer Research Center, Seattle, WA USA.
⁵ Walter Reed Army Institute of Research, Silver Spring, MD USA.

^# Contributed equally.

Abstract

The rapid development of COVID-19 vaccines and their deployment in less than a year is an unprecedented scientific, medical, and public health achievement. This rapid development leveraged knowledge from decades of HIV/AIDS research and advances. However, the search for an HIV vaccine that would contribute to a durable end to the HIV pandemic remains elusive. Here, we draw from the US government experience and highlight lessons learned from COVID-19 vaccine development, which include the importance of public-private partnerships, equitable inclusion of populations impacted by the infectious pathogen, and continued investment in basic research. We summarize key considerations for an accelerated and re-energized framework for developing a safe and efficacious HIV vaccine.

Keywords: HIV infections; Medical research; SARS-CoV-2; Viral infection.

Publication types

Review

Abstract

Publication types

Grants and funding